“Improving Outcomes in Hematologic Malignancies via Individualized Therapy”

Click the “Start Activity” button to indicate you have reviewed the CME/CE information for this activity.
Start Activity

Release Date: August 8, 2011
Expiration Date: August 8, 2012
Estimated Time to Complete Activity: 30 minutes
Minimum System Requirements:
  • Internet Explorer 7 (or higher)
  • Mozilla Firefox 4 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 6.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)
Target Audience
This activity has been designed to meet the educational needs of community-based hematologists, medical oncologists, oncology support staff (RNs, NPs, PAs), and other healthcare providers interested in treating and managing patients with hematologic malignancies.

Statement of Need
Due to the heterogeneous nature of hematologic malignancies and how patients may respond differently to similar treatments, individualizing patient therapy is essential in effectively managing and treating the disease. Additionally, treatment of hematologic malignancies can be complicated by several factors, including disease features and therapy side effects. Such complications create a clinical need for therapy to be individualized based on patient, disease, and treatment factors.

Educational Objectives
After completing this activity, the participant should be better able to:
  • Discuss the clinical features, including differential diagnoses, of the various hematologic malignancies
  • Describe recent advances in treatment for the various hematologic malignancies
  • Summarize the major patient-management issues associated with hematologic malignancies
  • Provide appropriate care and counsel for patients and their families

Presenting Faculty
Charles M. Farber, MD, PhD
Chief, Division Hematology Oncology
Carol G. Simon Cancer Center
Morristown Memorial Hospital
Morristown, New Jersey

Planning Committee Faculty
Charise Gleason, MSN, NP-C, AOCNP
Nurse Practitioner, Lead of BMT/Myeloma
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Method of Participation
During the period August 15, 2011 through August 15, 2012, participants must:
  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form
A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

There is no fee to participate in or to receive credit for this educational activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Charles M. Farber, MD, PhD

Has no real or apparent conflicts of interest to report.
Charise Gleason, MSN, NP-C, AOCNP

Consulting Fees: Merck & Co., Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN

Have no real or apparent conflicts of interest to report.

ECM: Patrick J. Crowley, Managing Director; Jodi Andrews, Associate Director, Educational Programs; Cassie Gangeri, Program Manager; Stef Stendardo, Contributing Author; Gay Boyle, Manager, Editorial Services

Have no real or apparent conflicts of interest to report.


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Cardiovascular & Metabolic Health Foundation (CMH), Educational Concepts in Medicine (ECM), and Millennium Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMH, ECM, and Millennium Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., and the Cardiovascular & Metabolic Health Foundation.